NEWS
Impactful technology
July 2024
The China National Intellectual Property Administration (CNIPA) issues HelixBind
patent number 202180018763.3 covering devices and methods for reliably storing and delivering
reagents in a diagnostic system.
MAY 2024
USPTO issues HelixBind patent US 11,975,320 covering devices for the direct detection and identification of microorganisms in complex matrices such as blood.
December 2023
USPTO issues HelixBind patent US 11,840,721 covering
improved methods for detecting microbial infections.
December 2023
HelixBind announces the award of $6 million of non-dilutive funding in 2023
to advance the company's RaPID diagnostic platform.
august 2023
USPTO issues HelixBind patent US 11,713,330 covering methods for ultrasensitive direct detection
of microorganisms, including Borrelia, the causative pathogen of Lyme Disease.
February 2023
USPTO issues HelixBind patent US 11,590,507 covering reagent carriers for fluidic systems.
December 2022
HelixBind announces $9 million in non-dilutive financing from the NIH in 2022 to support the
development of assays for the direct detection and identification of infections.
AUGUST 2022
USPTO issues HelixBind patent US 11,414,712 covering methods to identify microbial species
direct from complex specimens, such as blood.
August 2022
Japanese Patent Office (JPO) issues HelixBind patent JP 7073328 covering multiple aspects
of HelixBind’s sample-to-answer automated device.
March 2022
Japanese Patent Office (JPO) issues HelixBind patent JP 7046603 covering the company’s method
for the identification of microbial infections directly from human specimens.
MARCH 2022
The China National Intellectual Property Administration (CNIPA) issues HelixBind
patent number 201780016859.3 covering certain aspects of its integrated fluidic devices for
detecting and identifying of microorganisms.
august 2021
USPTO issues HelixBind patent US 11,091,814 covering the methods
to detect bacterial and/or fungal genomic material in a sample.